By using this site, you agree to the Privacy Policy and Terms of Use.
Accept

News Junction

Notification Show More
Font ResizerAa
  • Home
  • World News
    World NewsShow More
    “Cool” years are now hotter than the “warm” years of the past: tracking global temperatures through El Niño and La Niña
    “Cool” years are now hotter than the “warm” years of the past: tracking global temperatures through El Niño and La Niña
    April 28, 2025
    Commentary: Trump’s tariffs are an opportunity for Indonesia to advance its interests
    Commentary: Trump’s tariffs are an opportunity for Indonesia to advance its interests
    April 28, 2025
    Has he finally realised Putin is playing him, or is Trump just blowing in the wind?
    Has he finally realised Putin is playing him, or is Trump just blowing in the wind?
    April 28, 2025
    Pilgrims travel to Pope Francis’s tomb to remember the late pontiff | World News
    Pilgrims travel to Pope Francis’s tomb to remember the late pontiff | World News
    April 27, 2025
    Assessing the Dangers of a ‘New Nuclear Age’
    Assessing the Dangers of a ‘New Nuclear Age’
    April 27, 2025
  • Business
    BusinessShow More
    Ukraine blows up bridges to consolidate its positions in Russia
    Ukraine blows up bridges to consolidate its positions in Russia
    August 18, 2024
    Commentary: AI phones from Google and Apple will erode trust in everything
    Commentary: AI phones from Google and Apple will erode trust in everything
    August 18, 2024
    The most famous Indian Dishes – Insights Success
    The most famous Indian Dishes – Insights Success
    August 18, 2024
    Life on the road as a female long rides cyclist
    Life on the road as a female long rides cyclist
    August 18, 2024
    UK inflation rises to 2.2%
    UK inflation rises to 2.2%
    August 18, 2024
  • Cryptocurrency
    CryptocurrencyShow More
    Tariff Carnage Starting to Fulfill BTC’s ‘Store of Value’ Promise
    Tariff Carnage Starting to Fulfill BTC’s ‘Store of Value’ Promise
    April 28, 2025
    Price analysis 4/9: BTC, ETH, XRP, BNB, SOL, DOGE, ADA, LEO, LINK, TON
    Price analysis 4/9: BTC, ETH, XRP, BNB, SOL, DOGE, ADA, LEO, LINK, TON
    April 28, 2025
    Bitcoin trades at ‘40% discount’ as spot BTC ETF buying soars to B in one week
    Bitcoin trades at ‘40% discount’ as spot BTC ETF buying soars to $3B in one week
    April 28, 2025
    The cost of innovation — Regulations are Web3’s greatest asset
    The cost of innovation — Regulations are Web3’s greatest asset
    April 27, 2025
    The cost of innovation — Regulations are Web3’s greatest asset
    The cost of innovation — Regulations are Web3’s greatest asset
    April 27, 2025
  • Technology
    TechnologyShow More
    How to Improve Your Spotify Recommendations
    How to Improve Your Spotify Recommendations
    August 18, 2024
    X says it’s closing operations in Brazil
    X says it’s closing operations in Brazil
    August 18, 2024
    Supermoon set to rise: Top tips for amateur photographers | Science & Tech News
    Supermoon set to rise: Top tips for amateur photographers | Science & Tech News
    August 18, 2024
    Scientists Want to See Videos of Your Cat for a New Study
    Scientists Want to See Videos of Your Cat for a New Study
    August 18, 2024
    OpenAI’s new voice mode let me talk with my phone, not to it
    OpenAI’s new voice mode let me talk with my phone, not to it
    August 18, 2024
  • Entertainment
  • Sports News
  • People
  • Trend
Reading: Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
Share
Font ResizerAa

News Junction

  • World News
  • Business
  • Technology
  • Cryptocurrency
  • Trend
  • Entertainment
Search
  • Recent Headlines in Entertainment, World News, and Cryptocurrency – NewsJunction
  • World News
  • Business
  • Cryptocurrency
  • Technology
  • Entertainment
  • Sports News
  • People
  • Trend
Have an existing account? Sign In
Follow US
News Junction > Blog > Business > Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
Business

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

Published February 2, 2024
Share
3 Min Read
SHARE

Article content

SAN DIEGO & SHANGHAI — Sirius Therapeutics, announced it has dosed the first subject in a Phase 1, first-in-human clinical trial in Australia of SRSD107 on January 30th 2024, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. SRSD107 is the second clinical candidate in the company’s portfolio of next generation siRNA therapeutics to treat cardiovascular diseases. The company recently began clinical trials of SRSD101 in China for the treatment of dyslipidemia following IND clearance from the China National Medical Products Administration.

Article content

“This trial is based on in vivo studies that demonstrated a nearly 100% reduction of FXI levels for up to 6 months, without bleeding events, after a single subcutaneous dose,” said Dr. Qunsheng Ji, Sirius Therapeutics’ Chief Executive Officer. “The trial will provide an opportunity to evaluate SRSD107’s potential as a differentiated therapeutic for these common disorders globally.”

Article content

The SRSD107 Phase 1 study, which is being conducted in healthy volunteers in Australia, will evaluate SRSD107’s safety, tolerability, pharmacokinetics, and pharmacodynamics at single ascending doses and multiple ascending doses.

About Thromboembolic Disorders

Thrombosis, or blood clot formation, is the common underlying mechanism of most cases of myocardial infarction, ischemic stroke, and venous thromboembolism. According to a study in The Lancet of regional and global mortality, thromboembolic disorders are estimated to cause 1 in 4 deaths worldwide1.

About SRSD107

SRSD107 is a novel double-stranded small interfering ribonucleic acid (siRNA). Developed by Sirius Therapeutics, SRSD107 specifically targets coagulation factor XI (FXI) mRNA and inhibits FXI protein expression, thereby blocking the intrinsic coagulation pathway and promoting anticoagulant/anti-thrombotic effects. SRSD107 has been engineered for the potential to enable once or twice-a-year dosing.

About Sirius Therapeutics

Sirius is an innovative, clinical stage biotech company developing next generation siRNA therapy for global markets. We are dedicated to discovering and developing new treatment options for cardiovascular disease patients. Our most advanced products are SRSD107 for the treatment of thromboembolic disorders, and SRSD101 for the treatment of dyslipidemia. Founded in 2021 by a world-class leadership team and investors, Sirius has established an innovative discovery center in the United States and translational medicine center in China. Sirius has raised nearly US$100 million funding to date from OrbiMed, Creacion Ventures, Hankang Capital, Delos Capital, and the leadership team.

[1] Lozano R, Naghavi M, Foreman K, et al. Lancet. 2012;380, 2095-1128.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240201912539/en/

logo

Contacts

info@siriusrna.com

Official Website:
www.siriusrna.com

#distro

Share this article in your social network

#Sirius #Therapeutics #Begins #Phase #Clinical #Trial #NextGeneration #LongActing #Factor #siRNA #Anticoagulant #Treatment #Thromboembolic #Disorders

TAGGED:AnticoagulantbeginsclinicaldisordersfactorLongActingnextgenerationphaseSiriussiRNATherapeuticsThromboembolictreatmenttrial
Share This Article
Facebook Twitter Pinterest Whatsapp Whatsapp LinkedIn Email Copy Link Print
Share
What do you think?
Love0
Sad0
Happy0
Sleepy0
Angry0
Dead0
Wink0
Previous Article Recent Match Report – Sri Lanka vs Afghanistan Only Test 2023/24 Recent Match Report – Sri Lanka vs Afghanistan Only Test 2023/24
Next Article Meta and Amazon values surge as Huawei and folding phones take a bite out of Apple’s stock | Business News Meta and Amazon values surge as Huawei and folding phones take a bite out of Apple’s stock | Business News

You Might Also Like

Port of Dover warns EU border system has lasting “negative impacts”
Business

Port of Dover warns EU border system has lasting “negative impacts”

January 26, 2024
Getting to Know You: Ivo Gueorguiev, Co-founder, Paynetics
Business

Getting to Know You: Ivo Gueorguiev, Co-founder, Paynetics

August 5, 2024
Refurbishing Pickering nuclear station is right decision for Ontario
Business

Refurbishing Pickering nuclear station is right decision for Ontario

January 30, 2024
Wetherspoons closes more pubs with dozens across Britain earmarked for closure.. is your local calling last orders?
Business

Wetherspoons closes more pubs with dozens across Britain earmarked for closure.. is your local calling last orders?

August 2, 2023

About Us

NEWS JUNCTION (NewsJunction.xyz) Your trusted destination for global news. Stay informed with our timely and accurate reporting on diverse topics, including politics, technology, science, entertainment, sports, and more. Count on us for unbiased and reliable updates at your fingertips.

Quick Link

  • About
  • Disclaimer
  • Privacy Policy
  • Terms of Use
  • Contact

Top Categories

  • World News
  • Business
  • Technology
  • Entertainment
  • Cryptocurrency
  • Sports News
  • Trend
  • People

Subscribe

Subscribe to our newsletter to get our newest articles instantly!

    © 2023 News Junction.
    • Blog
    • Advertise
    • Contact
    Welcome Back!

    Sign in to your account

    Username or Email Address
    Password

    Lost your password?